Anavex Life Sciences Reports the EMA’s MAA Acceptance of Blarcamesine for Treating Alzheimer’s Disease
Shots:
- The EMA has accepted to review the MAA of blarcamesine (a small molecule given orally, QD) for treating Alzheimer’s disease
- Submission was based on the P-IIb/III (ANAVEX 2-73-AD-004) study and its 144wks. open-label extension (ATTENTION-AD) assessing blarcamesine for early Alzheimer’s disease
- Trial depicted improvement in ADAS-Cog13 scores by over 2 points at 48wks.; SIGMAR1 activation, restoring cellular homeostasis via autophagy plus a favorable safety profile offering a safe, MRI-free alternative to injectable anti-beta amyloid therapies
Ref: GlobeNewswire | Image: Anavex Life Sciences
Related News:- Nuvation Bio Reports the US FDA’s NDA Acceptance of Taletrectinib with Priority Review to Treat Advanced ROS1+ NSCLC
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
![Life Molecular Imaging’s [18F] PI-2620 Gains the US FDA’s Fast Track Designation for PET Imaging in Various Neurodegenerative Disorders](https://pharmashots.com/public/images/20240829173251_original_43.webp)
